Clinical Trials on Normal and Abnormal Tissue in Singapore

Total 440 results

Blueprint Medicines Corporation

Active, not recruiting

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Neoplasms | Neoplasms by Histologic Type | Lung Diseases | Neoplasms by Site | Adenocarcinoma | Carcinoma | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Neoplasms, Nerve Tissue | EGF-R Positive Non-Small Cell Lung... and other conditions

United States, Canada, Taiwan, Korea, Republic of, Singapore, Japan, United Kingdom, France, Netherlands, Spain
Novartis Pharmaceuticals

Completed

Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study (β-RELIEVED)

Acute Gout

Colombia, Switzerland, Germany, Russian Federation, Singapore, Australia, Belgium, Canada, Estonia, Guatemala, Latvia, Lithuania, Mexico, Norway, Poland, Sweden, Ukraine
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

France, Germany, Italy, Spain, United Kingdom, Hong Kong, United States, Colombia, Brazil, Canada, New Zealand, South Africa, Philippines, Russian Federation, Thailand, Singapore, Bulgaria, Mexico, Australia, Lithuania, Poland, Ar... and more
Genentech, Inc.

Unknown

A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)

Metastatic Breast Cancer

Australia, Spain, Greece, Mexico, Russian Federation, United States, Singapore, Canada, Peru, Taiwan, Korea, Republic of, Philippines, Netherlands, United Kingdom, France, Brazil, Ukraine, Sweden, Guatemala, Panama, Norway, Uruguay
Amryt Research Limited

Completed

Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa (EASE)

Epidermolysis Bullosa

United States, Spain, Israel, Australia, France, Denmark, Switzerland, Italy, Hong Kong, Argentina, Austria, Brazil, Chile, Colombia, Czechia, Georgia, Germany, Greece, Hungary, Ireland, Romania, Russian Federation, Serbia, Singapore, U... and more
Bristol-Myers Squibb

Completed

Effects of Abatacept in Patients With Early Rheumatoid Arthritis (AVERT-2)

Rheumatoid Arthritis

Italy, Sweden, Taiwan, United States, Peru, Germany, Mexico, Japan, Israel, Spain, Czechia, Argentina, Brazil, Colombia, Romania, Australia, France, Poland, Singapore, Russian Federation, South Africa, Canada, United Kingdom, Hungary, C... and more
Novartis Pharmaceuticals

Completed

A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.

Chronic Spontaneous Urticaria

Spain, Germany, France, Korea, Republic of, Turkey, Argentina, Slovakia, United States, Canada, Singapore
Bayer
ImmunoGen, Inc.; MorphoSys AG

Completed

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi)

Neoplasms

United States, Spain, United Kingdom, Korea, Republic of, Canada, France, Belgium, Australia, Singapore, Italy, Netherlands, Switzerland
Pfizer

Completed

Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)

Skin/Soft Tissue Infections | Methicillin Resistant Staphylococcus Aureus (MRSA)

United States, Spain, United Kingdom, Colombia, Italy, Chile, Argentina, Mexico, Belgium, Russian Federation, Brazil, Malaysia, Singapore, Portugal, South Africa, Venezuela
Bayer

Completed

Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer

Breast Neoplasms

Belgium, Spain, Hong Kong, Taiwan, Japan, United States, Austria, Singapore, Israel, United Kingdom, Italy, Korea, Republic of, France, Poland, Switzerland, Germany, Norway
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Hoffmann-La Roche

Completed

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Brazil, United Kingdom, Canada, Argentina, Mexico, Austria, Israel, Colombia, Peru, Russian Federation, Philippines, Puerto Rico, Germany, Greece, Poland, Spain, France, Singapore, China, South Africa, Hungary, Denmark, Finlan... and more
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Neoplasms, Breast

United Kingdom, United States, Peru, Israel, Poland, Russian Federation, Korea, Republic of, Thailand, Pakistan, Hungary, India, Canada, France, Mexico, Malaysia, Singapore
Genentech, Inc.

Completed

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Chronic Idiopathic Urticaria

Germany, United Kingdom, United States, Switzerland, Australia, New Zealand, Poland, Singapore
Novartis Pharmaceuticals

Recruiting

24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

Chronic Spontaneous Urticaria

United States, Singapore, Spain, Germany, Turkey, Italy, Hong Kong, China, Argentina, Malaysia, Thailand, Poland, Japan, Netherlands, South Africa, Chile, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve)

Breast Cancer

United States, Belgium, Italy, Spain, United Kingdom, Taiwan, Canada, Germany, Argentina, Israel, Korea, Republic of, Denmark, France, India, Chile, Netherlands, Singapore, Japan, Mexico
Genzyme, a Sanofi Company

Terminated

A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD)

Parkinson's Disease

United States, Austria, Canada, France, Germany, Greece, Israel, Italy, Japan, Norway, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom
Pyramid Biosciences

Terminated

Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Solid Tumor, Adult | Desmoplastic Small Round Cell Tumor | Brain Tumor, Primary

France, United States, Spain, Hong Kong, United Kingdom, Australia, Singapore, Germany, Korea, Republic of, Italy, Denmark
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
Pfizer

Completed

A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

Belgium, Spain, Germany, France, Hungary, Russian Federation, Singapore, Argentina, Austria, Bosnia and Herzegovina, Bulgaria, Chile, Colombia, Croatia, Czechia, Denmark, Hong Kong, Israel, Korea, Republic of, Netherlands, Poland, Slovaki... and more
Hoffmann-La Roche

Recruiting

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

Metastatic Melanoma | Non-small Cell Lung Cancer | Solid Tumors | Esophageal Squamous Cell Carcinoma

United States, Denmark, Israel, Portugal, Singapore, Spain, United Kingdom, Mexico, Korea, Republic of, Brazil, Turkey, Moldova, Republic of, Georgia
Pfizer

Terminated

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine

Breast Neoplasms

Australia, Canada, Bulgaria, Spain, Germany, Italy, Korea, Republic of, Turkey, Brazil, Colombia, Taiwan, Philippines, Singapore, Mexico, United Kingdom, Hong Kong, India, South Africa, Japan, France, Argentina, Chile, Peru
Novartis Pharmaceuticals

Recruiting

Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (NEPTUNUS-1)

Sjogren Syndrome

Brazil, Portugal, United States, Belgium, Spain, Germany, Korea, Republic of, Czechia, Mexico, France, Turkey, China, Guatemala, Austria, Chile, Poland, Singapore, Lithuania
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)

Chronic Plaque Psoriasis

Germany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Symptomatic Refractory Resistant Carcinoid Disease

United Kingdom, Belgium, Italy, Singapore, Austria, France, Israel, Sweden, Germany, Spain, Canada, Argentina, Poland, United States, Brazil, Norway
Genentech, Inc.

Completed

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Breast Cancer

Belgium, Israel, United States, Spain, Denmark, Germany, Hong Kong, Russian Federation, Australia, New Zealand, Korea, Republic of, Malaysia, Singapore, Italy, Czech Republic, France, Peru, Canada, United Kingdom, Chile, Thailand, Argentin... and more
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Novartis Pharmaceuticals

Completed

A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation (BELLE-4)

Breast Cancer

Belgium, France, Taiwan, Hungary, Germany, Singapore, Austria, Netherlands, Australia, Russian Federation, Spain, Canada, Israel, Japan, Korea, Republic of, Italy, United States, United Kingdom, Brazil, Hong Kong, Czech Republic, South...
Sermonix Pharmaceuticals Inc.

Recruiting

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

Metastatic Breast Cancer

United States, France, Belgium, Spain, Israel, Taiwan, United Kingdom, Korea, Republic of, Italy, Australia, Germany, Canada, Czechia, Hungary, Poland, Romania, Singapore, Turkey
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

Phase III Study in Refractory Behcet's Disease (SHIELD)

Behcet Disease

India, Turkey, Spain, Germany, Italy, France, Israel, Greece, Korea, Republic of, Hong Kong, United States, Egypt, Jordan, Singapore, Switzerland, Taiwan, Tunisia
AstraZeneca

Active, not recruiting

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive

United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Novartis Pharmaceuticals

Completed

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

Gouty Arthritis

Colombia, Spain, Taiwan, Russian Federation, Guatemala, Belgium, United States, Argentina, Czechia, Germany, Hungary, Poland, Portugal, Singapore, Slovakia, South Africa, Turkey, United Kingdom
Pfizer

Active, not recruiting

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

Melanoma

Canada, United States, Spain, Germany, Korea, Republic of, Australia, Czechia, Netherlands, France, Hungary, United Kingdom, Switzerland, Singapore, Russian Federation, Italy, Japan, Israel, Brazil, Portugal, Mexico, Greece, Argen... and more
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120)

Breast Cancer

United States, Korea, Republic of, United Kingdom, Australia, Belgium, China, Denmark, France, Hungary, Portugal, Spain, Taiwan, Thailand, Canada, Italy, Argentina, Brazil, Poland, Singapore, Germany, Greece, Hong Kong, Ukraine, Russian... and more
Kezar Life Sciences, Inc.

Recruiting

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

Lupus Nephritis

United States, Korea, Republic of, Australia, Malaysia, Taiwan, South Africa, China, Singapore, United Kingdom, Puerto Rico, Croatia, India, Greece, Spain, Brazil, Philippines, Guatemala, Argentina, Portugal, Colombia
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Metastatic Breast Cancer

United States, Korea, Republic of, Spain, Canada, Brazil, China, Singapore, Turkey, India, Argentina, Australia, Belgium, Finland, Hong Kong, South Africa, Italy, United Kingdom, Poland, Taiwan, Colombia, France, Germany, Mexico
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

United States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
Pfizer

Terminated

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

Psoriasis

United States, Spain, Korea, Republic of, Taiwan, Canada, Poland, Belgium, Denmark, Germany, Serbia, United Kingdom, France, Czechia, Hungary, Mexico, Colombia, Russian Federation, Croatia, Singapore, Australia, Austria, Slovakia, S... and more
Celcuity, Inc.

Recruiting

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)

Breast Cancer

Korea, Republic of, United States, Belgium, United Kingdom, Taiwan, France, Italy, Australia, Singapore, Argentina, Canada, India, Mexico, Czechia, Spain, Austria, Bulgaria, Germany, Hungary, Poland, Brazil, Greece, Romania
Hoffmann-La Roche
European Organisation for Research and Treatment of Cancer - EORTC; NCIC Clinical... and other collaborators

Completed

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer (HERA)

Breast Cancer

France, Spain, Switzerland, Greece, Italy, Korea, Republic of, Australia, Canada, Poland, Belgium, United Kingdom, Netherlands, Germany, Chile, Ireland, Portugal, South Africa, Sweden, China, Austria, Hungary, Brazil, Colombia, Thailand, Denma... and more
Genzyme, a Sanofi Company

Recruiting

Mucopolysaccharidosis I (MPS I) Registry

Mucopolysaccharidosis I (MPS I)

Croatia, United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, France, Hong Kong, India, Indonesia, Korea, Republic of, Kuwait, Lebanon, Malaysia, Netherlands, Pakistan, Philippines, Poland, Saudi Arabia, Singapore, Slovaki... and more
Hoffmann-La Roche

Active, not recruiting

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

Triple Negative Breast Neoplasms

Korea, Republic of, Italy, China, Finland, France, Hungary, Spain, United Kingdom, Argentina, United States, Bosnia and Herzegovina, Brazil, Chile, Germany, Poland, Russian Federation, Morocco, Mexico, Portugal, Serbia, Turkey, South... and more
Puma Biotechnology, Inc.

Completed

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Breast Cancer | Advanced Breast Cancer

Korea, Republic of, Taiwan, Hong Kong, United States, Japan, Croatia, United Kingdom, Hungary, Australia, Canada, Serbia, Singapore, South Africa, Poland, Spain, Russian Federation, Romania, Austria, Belgium, Bulgaria, Czechia, Fr... and more
Day One Biopharmaceuticals, Inc.
SIOPe Brain Tumor Group LOGGIC Consortium

Recruiting

DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

Low-grade Glioma

United States, Korea, Republic of, France, Germany, Spain, United Kingdom, Belgium, Denmark, Canada, Italy, Finland, Australia, Ireland, Switzerland, Netherlands, Czechia, Greece, New Zealand, Slovenia, Sweden, Hungary, Singapore, A... and more
Novartis Pharmaceuticals

Terminated

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Melanoma | Head and Neck Cancer | Pancreatic Cancer | Urothelial Cancer | NSCLC, Non Small Cell Lung Cancer | RCC, Renal Cell Cancer | DLBCL, Diffused Large B Cell Lymphoma | MSS, Microsatellite Stable Colon Cancer | TNBC, Triple Negative Breast Cancer | mCRPC, Metastatic Castration Resistant Prostate...

Belgium, Italy, Taiwan, Germany, Spain, United States, Argentina, Australia, Austria, Czechia, France, Japan, Netherlands, Switzerland, Singapore
Novartis Pharmaceuticals

Recruiting

Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis (SIRIUS-LN)

Lupus Nephritis

China, United States, Spain, Germany, Korea, Republic of, Italy, Thailand, Hungary, Argentina, Brazil, Singapore, Taiwan, France, Vietnam, Malaysia, Lithuania, Canada, India, Colombia, Romania, United Kingdom, Czechia, Guatemala, Mexico, Eston... and more
Merck Sharp & Dohme LLC

Active, not recruiting

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Triple Negative Breast Neoplasms

Brazil, Canada, United States, United Kingdom, Taiwan, Australia, Colombia, France, Germany, Ireland, Israel, Italy, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Singapore, Spain, Sweden, Turkey

Clinical Trials on Normal and Abnormal Tissue in Singapore

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations